Company database

HLB bioStep offers Preclinical PK/TK, mass spectrometry, flow cytometry and biomarkers. Services should be matched to the intended study and assay requirements.

N

Novotech

Compare

Novotech offers Large-molecule PK, ADA, neutralizing antibodies and clinical laboratory testing. Services should be matched to the intended study and assay requirements.

L

Lablytica

Compare

Lablytica offers Regulated small- and large-molecule bioanalysis and biomarkers. Services should be matched to the intended study and assay requirements.

A

Admescope

Compare

Admescope offers Non-GLP quantitative bioanalysis, DMPK and biomarker studies. Services should be matched to the intended study and assay requirements.

CB

Chimera Biotec

Compare

Chimera Biotec offers Ultrasensitive immunoassays, large-molecule bioanalysis and biomarkers. Services should be matched to the intended study and assay requirements.

OB

Oxford BioDynamics

Compare

Oxford BioDynamics offers Epigenetic biomarker discovery and 3D-genomics research services. Services should be matched to the intended study and assay requirements.

B

Biognosys

Compare

Biognosys offers Mass-spectrometry proteomics, metabolomics and biomarker research. Services should be matched to the intended study and assay requirements.

M

Metabolon

Compare

Metabolon offers Metabolomics and biomarker discovery and analysis. Services should be matched to the intended study and assay requirements.

A

Allumiqs

Compare

Allumiqs offers Mass-spectrometry proteomics, multiomics and biomarker discovery. Services should be matched to the intended study and assay requirements.

SH

Syneos Health

Compare

Syneos Health offers Small- and large-molecule PK, immunogenicity and biomarker testing. Services should be matched to the intended study and assay requirements.

Develops RNA-activation and siRNA medicines. Representative programs include RAG-01 for NMIBC, RAG-18 for DMD and RAG-17 for SOD1-associated ALS. Stages are tied to dated issuer disclosures; this is not a complete pipeline or independent efficacy validation.

Wholly owned Nippon Shinyaku subsidiary developing and commercializing rare-disease medicines, including DMD exon-skipping programs.

GC

GCP ClinPlus

Compare

Discloses China clinical operations, biometrics, regulatory and safety services, with explicit China IIT support for international developers, including cell and gene therapies. A US subsidiary and international partner network support cross-border engagement.

China-origin global CRO. Its China service page describes Phase I–IV work, site start-up, operations and biometrics for local and global sponsors. Global trial experience does not establish a specific IIT track record.

International CRO incorporating China-origin dMed. Discloses China operational strength and connected development between China, the US and Europe.

Cross-border CRO with China operations. Team biographies reference Phase I–IV and IIT experience. Staff experience is not proof of company-level IIT delivery; verify the contracting entity and China project lead.

China clinical CRO with biometrics and trial management capabilities. A Medidata partnership announcement supports its clinical technology and data-standardization approach; confirm international sponsor references and IIT staffing directly.

JC

JOINN Clinical

Compare

JOINN’s corporate disclosures include clinical trials and pharmacovigilance. Verify the clinical team and contracting entity; group GLP toxicology credentials do not establish clinical GCP execution capability.

China full-service clinical CRO disclosing a Shanghai entity and US subsidiary, targeting overseas-sponsored China studies. Confirm current staffing, sponsor references and delivery entity.

China clinical CRO with a Medidata partner profile and a Micron alliance announcement supporting international collaboration. Proswell is a separate company from GCP ClinPlus.

China-origin CRO disclosing international branches and operations, regulatory, writing and biometrics services. Public materials describe China–US and multi-country submissions; confirm inbound China and IIT experience.

China clinical CRO whose English site describes domestic and overseas clients and hospital-initiated research involving international sites. This supports investigator-led experience, with current commercial IIT scope to confirm.

SIIP’s official business page identifies Shanghai Yilinsi clinical services covering Phase I–IV, human PK, bioequivalence and international multicentre studies. Confirm English project staffing and recent overseas sponsor references.

China clinical platform formerly associated with WuXi AppTec, now part of Emerald Clinical and operating as Hongyi Clinical. Consolidated with historical WuXi Clinical rather than counted as a separate current WuXi subsidiary.